Background: It is important to distinguish between responders to standard treatment and non-responders Hodgkin's disease (HD) patients. Patients and Methods: Between June 2003–September 2004, in our institute, 40 newly-diagnosed patients with advanced stage HD were consecutively treated with ABVD chemotherapy for six cycles. All these patients underwent staging/restaging: computed tomography (CT) and positron emission tomography (PET) at time 0, PET after two cycles, CT and PET after four and six cycles. Results: After two cycles (PET-2), the PET was negative in 28/40 (70%), positive in 8/40 (20%), and minimal residual uptake (MRU) was present in the remaining four (10%) patients. After treatment, among eight patients who were PET-2+, seven showed refractory disease and one had relapse after 3 months. All four patients with MRU at the PET-2 became PET_ during the further four cycles and, after treatment, three were in complete response (CR) and one relapsed after 5 months. All 28 PET negative patients at the PET-2 remained PET negative and all of them were in CR after treatment. Conclusions: The PET use for early (after two cycles) response assessment in HD patients is a significant step forward and has the potential to help physicians make crucial decisions about further treatment.

Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients.

ZINZANI, PIER LUIGI;TANI, MONICA;FANTI, STEFANO;ALINARI, LAPO;MARCHI, ENRICA;STEFONI, VITTORIO;FINA, MARIAPAOLA;PILERI, STEFANO;BACCARANI, MICHELE
2006

Abstract

Background: It is important to distinguish between responders to standard treatment and non-responders Hodgkin's disease (HD) patients. Patients and Methods: Between June 2003–September 2004, in our institute, 40 newly-diagnosed patients with advanced stage HD were consecutively treated with ABVD chemotherapy for six cycles. All these patients underwent staging/restaging: computed tomography (CT) and positron emission tomography (PET) at time 0, PET after two cycles, CT and PET after four and six cycles. Results: After two cycles (PET-2), the PET was negative in 28/40 (70%), positive in 8/40 (20%), and minimal residual uptake (MRU) was present in the remaining four (10%) patients. After treatment, among eight patients who were PET-2+, seven showed refractory disease and one had relapse after 3 months. All four patients with MRU at the PET-2 became PET_ during the further four cycles and, after treatment, three were in complete response (CR) and one relapsed after 5 months. All 28 PET negative patients at the PET-2 remained PET negative and all of them were in CR after treatment. Conclusions: The PET use for early (after two cycles) response assessment in HD patients is a significant step forward and has the potential to help physicians make crucial decisions about further treatment.
2006
Zinzani PL.; Tani M.; Fanti S.; Alinari L.; Musuraca G.; Marchi E.; Stefoni V.; Castellucci P.; Fina M.; Farshad M.; Pileri S.; Baccarani M.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/28668
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 24
  • Scopus 131
  • ???jsp.display-item.citation.isi??? 122
social impact